Search Clinical Trials in the European Union

Duration
Visits
Phase
Intake methods
No Placebo
Drugs
Locations
Clinical Specialty
1721-1740 of 2,251 trials

Histiocytosis in Children: Trametinib Study

We are testing the safety and effectiveness of trametinib in children with refractory histiocytosis. The goal is to find the best dosage and timing for treatment after other therapies have failed.

Erdheim-Chester DiseaseRosai-Dorfman SyndromeLangerhans' Cell Histiocytosis>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesOncologyPediatrics

Chronic Lung Disease in Premature Babies: OHB-607 Study

We are testing a new drug to see if it helps reduce lung disease in extremely premature infants compared to standard care. The study aims to improve their overall health and development.

Chronic Lung Disease6-12 monthsEfficacy phase (II)≤5 visitsNo PlaceboStandard MedicinesCost ReimbursementPartially RemotePediatricsPulmonology

Atrial Fibrillation After CABG: Anticoagulant Study

We are studying whether adding anticoagulant medications helps prevent blood clots in patients with new-onset atrial fibrillation after heart surgery. This trial aims to ensure safety and effectiveness in managing this condition.

Atrial FibrillationNew-Onset Post-Operative Atrial Fibrillation after CABG6-12 monthsMonitoring phase (IV)No PlaceboInvestigational MedicinesPartially RemoteCardiologyInternal Medicine

Iptacopan for Pediatric Patients with PNH

We are studying the safety and tolerability of iptacopan in children with PNH. The trial will also evaluate its effects on hemoglobin levels and the need for blood transfusions.

Paroxysmal Nocturnal Hemoglobinuria (PNH)6-12 monthsConfirmation phase (III)11-15 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesPartially RemoteHematologyInternal Medicine

Lung Cancer: Pembrolizumab Maintenance Study

We are studying whether continuing pembrolizumab treatment helps patients with stage IV lung cancer maintain disease control after initial chemotherapy. This trial will also look at the quality of life and side effects experienced by participants.

Non-Small Cell Lung Cancer>2 yearsEfficacy phase (II)Confirmation phase (III)No PlaceboStandard MedicinesOncology

Rapamycin for Drug-Resistant Epilepsy in Children

We are studying the safety and effectiveness of rapamycin for children with drug-resistant epilepsy caused by rare central nervous system diseases. This trial aims to find better treatment options for these challenging conditions.

Epilepsy and Related Disorders>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesNeurology

High-Grade Glioma in Children: Rapamycin Study

We are evaluating the safety and effectiveness of rapamycin for treating high-grade gliomas in children. This study aims to understand how well it works and if genetic factors play a role in treatment response.

High Grade Glioma>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesOncologyPediatrics

DIPG Treatment: Targeted Drug Study for Children

We are testing how well certain drugs work for children with diffuse intrinsic pontine glioma (DIPG) based on their tumor's genetic makeup. The goal is to find safer and more effective treatments tailored to individual patients.

Diffuse Intrinsic Pontine Glioma>2 yearsEfficacy phase (II)No PlaceboInvestigational MedicinesNeurologyOncologyPediatrics

Myelofibrosis: Study of Pacritinib vs. Standard Treatment

We are investigating whether pacritinib can better reduce spleen size and improve symptoms in patients with myelofibrosis. This trial is for those with severe low platelet counts and compares pacritinib to physician's choice of therapy.

Post-Polycythaemia Vera MyelofibrosisPrimary MyelofibrosisPost-Essential Thrombocythaemia Myelofibrosis3-6 monthsConfirmation phase (III)6-10 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementHematologyOncology

Acute Cholecystitis: Antibiotic Treatment Comparison

We are studying whether a single dose of antibiotics before gallbladder surgery is as effective as continuous antibiotics in preventing infections. This trial aims to improve patient outcomes during and after surgery.

Acute Cholecystitis>2 yearsConfirmation phase (III)No PlaceboStandard MedicinesGastroenterologyInternal Medicine

Dystonia: Botulinum Toxin for Arm Tremors

We are exploring how different tests and imaging techniques can help determine the effectiveness of botulinum toxin for treating arm tremors in people with dystonia. This study aims to improve treatment options for those affected.

Dystonic Tremor Syndrome6-12 monthsMonitoring phase (IV)≤5 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementNeurology

Oligometastatic Peritoneal Gastric Cancer: PIPAC Treatment Study

We are studying whether adding pressurized intraperitoneal aerosol chemotherapy (PIPAC) to standard chemotherapy helps patients with oligometastatic peritoneal gastric cancer have better surgery outcomes and longer survival.

Metastatic Gastric Adenocarcinoma1-2 yearsConfirmation phase (III)Post-Trial Drug AccessNo PlaceboStandard MedicinesGastroenterologyOncology

Lung Cancer Treatment: Chemotherapy + Atezolizumab

We are studying a combination of chemotherapy and atezolizumab for patients with stage IIIA and IIIB non-small cell lung cancer. This trial aims to see if this approach improves survival and treatment outcomes before and after surgery.

Non-small Cell Lung Cancer>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesOncology

Cardiac Arrest: Ketamine vs. Propofol Sedation

We are studying whether ketamine sedation can better protect the brain and improve survival compared to propofol in patients resuscitated from cardiac arrest. This trial looks at outcomes at discharge and 180 days later.

Out-of-Hospital Cardiac Arrest1-2 yearsConfirmation phase (III)Monitoring phase (IV)No PlaceboStandard MedicinesPartially RemoteCardiologyNeurology

Nevoid Basal Cell Carcinoma Syndrome: Sonidegib Treatment Study

We are studying the effects of Sonidegib on patients with Nevoid Basal Cell Carcinoma Syndrome and sporadic basal cell carcinoma. The trial will assess treatment effectiveness, safety, and quality of life improvements.

Nevoid Basal Cell Carcinoma Syndrome6-12 monthsEfficacy phase (II)6-10 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesOncology

Crohn's Disease: Adalimumab Treatment Study

We are comparing a new approach using adalimumab for newly diagnosed Crohn's disease patients against standard treatments. The goal is to see which method is safer and more effective in the long run.

Crohn's Disease3-6 monthsMonitoring phase (IV)≤5 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesPartially RemoteGastroenterologyInternal Medicine

Efgartigimod for Early Treatment of Generalized Myasthenia Gravis

We are studying whether efgartigimod can improve daily activities and quality of life for patients with generalized myasthenia gravis and specific antibodies. This trial will help us understand its effectiveness and tolerability as an early treatment option.

Generalized Myasthenia Gravis6-12 monthsMonitoring phase (IV)11-15 visitsNo PlaceboStandard MedicinesPartially RemoteNeurology

RR001 Gene Therapy for Locally Advanced Pancreatic Cancer

We are studying a new gene therapy combined with chemotherapy to see if it is safe and effective for patients with locally advanced pancreatic cancer. The trial will help determine the best dose and how well this treatment works.

Pancreatic CancerLocally Advanced Pancreatic Cancer>2 yearsSafety phase (I)Efficacy phase (II)No PlaceboInvestigational MedicinesOncology

Huntington's Disease: Innovative Biomarker Study

We are exploring new imaging and cognitive markers to better understand how Huntington's disease progresses. This study aims to identify effective ways to track the disease from early stages.

Huntington's DiseaseConfirmation phase (III)6-10 visitsNo PlaceboInvestigational MedicinesCost ReimbursementNeurologyPsychiatry

Multiple Myeloma: Belantamab Mafodotin vs. Daratumumab

We are studying a new treatment combination for people with newly diagnosed multiple myeloma who cannot have stem cell transplants. The goal is to see if it works better and is safer than the current standard treatment.

Multiple MyelomaConfirmation phase (III)11-15 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteHematologyOncology